– CNBC
HC Wainwright & Co. Maintains Buy on Cerevel Therapeutics Hldg, Lowers Price Target to $48
HC Wainwright & Co. analyst Douglas Tsao maintains Cerevel Therapeutics Hldg (NASDAQ:CERE) with a Buy and lowers the price target from $50 to $48.